ATE474589T1 - Angiogene peptide und ihre verwendungen - Google Patents
Angiogene peptide und ihre verwendungenInfo
- Publication number
- ATE474589T1 ATE474589T1 AT04791852T AT04791852T ATE474589T1 AT E474589 T1 ATE474589 T1 AT E474589T1 AT 04791852 T AT04791852 T AT 04791852T AT 04791852 T AT04791852 T AT 04791852T AT E474589 T1 ATE474589 T1 AT E474589T1
- Authority
- AT
- Austria
- Prior art keywords
- angiogenic peptides
- peptide
- peptides
- amino acid
- angiogenic
- Prior art date
Links
- 102000008076 Angiogenic Proteins Human genes 0.000 title 1
- 108010074415 Angiogenic Proteins Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51489503P | 2003-10-29 | 2003-10-29 | |
| US55855804P | 2004-04-02 | 2004-04-02 | |
| PCT/IL2004/000992 WO2005039616A1 (en) | 2003-10-29 | 2004-10-28 | Angiogenic peptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE474589T1 true ATE474589T1 (de) | 2010-08-15 |
Family
ID=34527062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04791852T ATE474589T1 (de) | 2003-10-29 | 2004-10-28 | Angiogene peptide und ihre verwendungen |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7473682B2 (de) |
| EP (1) | EP1677813B1 (de) |
| JP (1) | JP2008500015A (de) |
| AT (1) | ATE474589T1 (de) |
| DE (1) | DE602004028266D1 (de) |
| WO (1) | WO2005039616A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008500015A (ja) * | 2003-10-29 | 2008-01-10 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | 血管形成ペプチドおよびその使用 |
| ES2531483T3 (es) | 2005-06-15 | 2015-03-16 | The Ohio State University Research Foundation | Péptidos HER-2 |
| DE102005031755B9 (de) * | 2005-07-01 | 2010-04-08 | Technische Universität Dresden | Salmonella spp. bindende Peptide, dafür kodierende Nukleinsäuren, deren Verwendungen und Verfahren und Kits zur Anreicherung, Immobilisierung und zum Nachweis von Salmonella spp. |
| CN101319008B (zh) * | 2005-09-27 | 2010-12-01 | 南开大学 | 与肿瘤转移细胞特异性结合的多肽及其应用 |
| CN100486991C (zh) * | 2005-09-27 | 2009-05-13 | 南开大学 | 与肿瘤转移细胞特异性结合的多肽及其应用 |
| JP5186632B2 (ja) * | 2006-10-19 | 2013-04-17 | ブリッタ ハーディ， | 血管形成を誘導するための組成物および方法 |
| WO2010052715A2 (en) * | 2008-11-07 | 2010-05-14 | Ramot At Tel Aviv University Ltd. | Devices and methods for local treatment of cardiovascular diseases |
| US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
| EP2385057A1 (de) * | 2010-05-05 | 2011-11-09 | Centre National de la Recherche Scientifique | Peptidderivate zur Biofunktionalisierung von Siliciumsubstraten und deren Anwendungen |
| US10329327B2 (en) | 2010-12-06 | 2019-06-25 | Massachusetts Institute Of Technology | Tricalcium phosphate binding peptides and uses thereof |
| DE102011003944A1 (de) | 2011-02-10 | 2012-08-16 | Oxprotect Gmbh | Detektion und Entfernung von missgefalteten Proteinen/Peptiden |
| EP3864025B1 (de) | 2018-10-12 | 2024-05-08 | Theradaptive, Inc. | Polypeptide mit einer beta-tricalciumphosphatbindenden sequenz und deren verwendungen |
| CN115916239A (zh) | 2020-04-15 | 2023-04-04 | 治疗调适公司 | 用于靶向治疗性递送至骨的组合物和方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638911B1 (en) * | 1998-05-05 | 2003-10-28 | Adherex Technologies Inc. | Compounds and methods for modulating desmosomal cadherin-mediated functions |
| EP1136082A1 (de) | 2000-03-24 | 2001-09-26 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Lokalen Arzneistoffabgabe |
| EP1355921A2 (de) * | 2000-06-29 | 2003-10-29 | North Shore-Long Island Jewish Health System | Modulatoren der zellulären proliferation und angiogenese, verfahren zu ihrer verwendung und ihre identifikation |
| US20030113714A1 (en) * | 2001-09-28 | 2003-06-19 | Belcher Angela M. | Biological control of nanoparticles |
| AU2002331890A1 (en) * | 2001-09-20 | 2003-04-01 | University Of Rochester | Compositions and methods involved in bone growth |
| WO2003037172A2 (en) | 2001-11-01 | 2003-05-08 | Gpc Biotech Inc. | Endothelial-cell binding peptides for diagnosis and therapy |
| AU2003213246A1 (en) * | 2002-02-21 | 2003-09-09 | University Of Virginia Patent Foundation | Bone targeting peptides |
| US20030221931A1 (en) * | 2002-02-28 | 2003-12-04 | Steve Marsh | Sliding device |
| JP2008500015A (ja) * | 2003-10-29 | 2008-01-10 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | 血管形成ペプチドおよびその使用 |
| US7531505B2 (en) * | 2006-01-11 | 2009-05-12 | Affinergy, Inc. | Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices |
| US20080047370A1 (en) * | 2006-08-07 | 2008-02-28 | Vickery James H Jr | Sampling apparatus for constituents in natural gas lines |
| JP5186632B2 (ja) * | 2006-10-19 | 2013-04-17 | ブリッタ ハーディ， | 血管形成を誘導するための組成物および方法 |
-
2004
- 2004-10-28 JP JP2006537555A patent/JP2008500015A/ja active Pending
- 2004-10-28 DE DE602004028266T patent/DE602004028266D1/de not_active Expired - Lifetime
- 2004-10-28 EP EP04791852A patent/EP1677813B1/de not_active Expired - Lifetime
- 2004-10-28 US US10/577,679 patent/US7473682B2/en not_active Expired - Fee Related
- 2004-10-28 WO PCT/IL2004/000992 patent/WO2005039616A1/en not_active Ceased
- 2004-10-28 AT AT04791852T patent/ATE474589T1/de not_active IP Right Cessation
-
2008
- 2008-11-28 US US12/292,876 patent/US20090163405A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1677813A1 (de) | 2006-07-12 |
| US20070082849A1 (en) | 2007-04-12 |
| US7473682B2 (en) | 2009-01-06 |
| WO2005039616A1 (en) | 2005-05-06 |
| JP2008500015A (ja) | 2008-01-10 |
| US20090163405A1 (en) | 2009-06-25 |
| EP1677813B1 (de) | 2010-07-21 |
| DE602004028266D1 (de) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE280826T1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
| MX2010002001A (es) | Peptido cdca1 y agente farmaceutico que comprende elmismo. | |
| ATE368053T1 (de) | Antimikrobielle peptide | |
| DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
| WO2009025116A1 (ja) | Cdh3ペプチド及びこれを含む薬剤 | |
| ATE495247T1 (de) | Chromoprotein und fluoroproteine | |
| DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| CY1109946T1 (el) | Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων | |
| ATE466871T1 (de) | Biologisch aktive peptide | |
| DE60329115D1 (de) | Tumorantigenprotein und dessen verwendung | |
| DK1504036T3 (da) | Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet | |
| ATE362769T1 (de) | Lineare kationische peptide mit fungizider wirksamkeit | |
| NZ591827A (en) | Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject | |
| SE9700301D0 (sv) | New compound | |
| GB0207644D0 (en) | Peptides and their use | |
| ATE521635T1 (de) | Physiologisch wirksamer komplex mit tnf aktivität | |
| EP1796707A4 (de) | Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren | |
| DE602006017806D1 (de) | Behandlung von neurodegeneration | |
| SG170757A1 (en) | Polypeptide having esterase activity and recombinant esterase and use thereof | |
| ATE305478T1 (de) | Topoisomerase-ii inhibitoren | |
| DE60008749D1 (de) | Therapeutische peptide aus untersequenzen von bpi | |
| TW200611913A (en) | Biologically active peptides (Ⅲ) | |
| WO2004058812A3 (en) | Ribose-phosphate pyrophosphokinase polypeptides and structures | |
| DE60135971D1 (de) | Mit wt1 interagierendes protein, wtip |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |